Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
NEW YORK (Reuters Health) – While angiotensin receptor blockers (ARBs) as a class do not appear to be associated with an increased malignancy risk in patients with diabetes,…
NEW YORK (Reuters Health) – Some patients with metastatic clear-cell renal cancer appear to fare relatively well when treated with sunitinib before undergoing planned nephrectomy — even though…
NEW YORK (Reuters Health) – Using intra-arterial chemotherapy to treat retinoblastoma can produce a “dramatic response,” but also comes with the risk of both mild and severe side…
NEW YORK (Reuters Health) – Women who are positive for human papilloma virus (HPV) and have low-grade cervical cytological abnormalities but normal colposcopic findings are at low risk…
NEW YORK (Reuters Health) – While partial nephrectomy remains the gold standard for treatment of small renal masses, laparoscopic cryoablation is a good option for selected patients, an…
NEW YORK (Reuters Health) – Hysteroscopy using narrow-band imaging (NBI) technology may be more sensitive than white-light imaging (WLI) for diagnosing endometrial cancer and hyperplasia, hint results of…
NEW YORK (Reuters Health) – After chemotherapy-induced remission of follicular lymphoma, vaccination with a patient-specific tumor-derived antigen improves disease-free survival, a multicenter team has shown. Furthermore, the vaccine…
NEW YORK (Reuters Health) – The longitudinal decline in lung function seen in patients with common variable immunodeficiency and X-linked agammaglobulinemia is related to immunoglobulin replacement level and…
NEW YORK (Reuters Health) – Very small breast tumors that generate extensive lymph node involvement may be more biologically aggressive than larger tumors with the same degree of…
NEW YORK (Reuters Health) – Results of a meta-analysis confirm that the oral tyrosine kinase inhibitor gefitinib is effective as first-line therapy in patients with advanced non-small-cell lung…
